UK markets closed

Hanall Biopharma Co., Ltd. (009420.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
35,150.00+1,600.00 (+4.77%)
At close: 03:30PM KST
Currency in KRW

Valuation measures4

Market cap (intra-day) 1.78T
Enterprise value 1.73T
Trailing P/E 509.42
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)13.25
Price/book (mrq)9.57
Enterprise value/revenue 12.80
Enterprise value/EBITDA 265.16

Trading information

Stock price history

Beta (5Y monthly) 0.87
52-week change 355.53%
S&P500 52-week change 326.16%
52-week high 346,750.00
52-week low 30.00
50-day moving average 335,648.00
200-day moving average 333,119.25

Share statistics

Avg vol (3-month) 3574.38k
Avg vol (10-day) 3246.16k
Shares outstanding 550.71M
Implied shares outstanding 650.71M
Float 834.5M
% held by insiders 138.31%
% held by institutions 118.92%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 210:1
Last split date 303 May 2006

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 2.60%
Operating margin (ttm)-13.93%

Management effectiveness

Return on assets (ttm)0.48%
Return on equity (ttm)1.98%

Income statement

Revenue (ttm)134.91B
Revenue per share (ttm)2,661.36
Quarterly revenue growth (yoy)5.30%
Gross profit (ttm)N/A
EBITDA 4.99B
Net income avi to common (ttm)3.51B
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)56.5B
Total cash per share (mrq)1,114.49
Total debt (mrq)1.29B
Total debt/equity (mrq)0.69%
Current ratio (mrq)3.02
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)29.64B
Levered free cash flow (ttm)4.85B